{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T03:13:53Z","timestamp":1795230833160,"version":"4.10.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-57965-6","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T02:11:17Z","timestamp":1742782277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Yixuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjie","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peishan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-4890","authenticated-orcid":false,"given":"Wanliang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"57965_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/cells9030618","volume":"9","author":"CR Lichtenstern","year":"2020","unstructured":"Lichtenstern, C. R. et al. Immunotherapy, inflammation and colorectal cancer. Cells 9, 618 (2020).","journal-title":"Cells"},{"key":"57965_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.critrevonc.2010.01.010","volume":"74","author":"R Labianca","year":"2010","unstructured":"Labianca, R. et al. Colon cancer. Crit. Rev. Oncol. Hematol. 74, 106\u2013133 (2010).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"57965_CR3","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.1016\/S0959-8049(11)70183-6","volume":"47","author":"A Stein","year":"2011","unstructured":"Stein, A. et al. Current standards and new trends in the primary treatment of colorectal cancer. Eur. J. Cancer 47, S312\u2013S314 (2011).","journal-title":"Eur. J. Cancer"},{"key":"57965_CR4","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(10)60353-4","volume":"375","author":"D Cunningham","year":"2010","unstructured":"Cunningham, D. et al. Colorectal cancer. Lancet 375, 1030\u20131047 (2010).","journal-title":"Lancet"},{"key":"57965_CR5","first-page":"175","volume":"19","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data. Cancer Biol. Med. 19, 175\u2013186 (2021).","journal-title":"Cancer Biol. Med."},{"key":"57965_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"57965_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"57965_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"57965_CR9","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"57965_CR10","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis, D. A. et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J. Clin. Endocrinol. Metab. 102, 2770\u20132780 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"57965_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. et al. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"57965_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. et al. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"57965_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"57965_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/gutjnl-2016-311421","volume":"66","author":"Y Masugi","year":"2017","unstructured":"Masugi, Y. et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 66, 1463\u20131473 (2017).","journal-title":"Gut"},{"key":"57965_CR15","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"57965_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz, H. J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J. Clin. Oncol. 40, 161\u2013170 (2022).","journal-title":"J. Clin. Oncol."},{"key":"57965_CR17","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"57965_CR18","doi-asserted-by":"publisher","first-page":"e2149040","DOI":"10.1001\/jamanetworkopen.2021.49040","volume":"5","author":"NB Mettu","year":"2022","unstructured":"Mettu, N. B. et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial. JAMA Netw. Open 5, e2149040 (2022).","journal-title":"JAMA Netw. Open"},{"key":"57965_CR19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti, C. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 23, 876\u2013887 (2022).","journal-title":"Lancet Oncol."},{"key":"57965_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849\u2013861 (2019).","journal-title":"Lancet Oncol."},{"key":"57965_CR21","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/annonc\/mdz113","volume":"30","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann. Oncol. 30, 1134\u20131142 (2019).","journal-title":"Ann. Oncol."},{"key":"57965_CR22","doi-asserted-by":"crossref","unstructured":"Diaz, L. A., Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659\u2013670 (2022).","DOI":"10.1016\/S1470-2045(22)00197-8"},{"key":"57965_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/gastro\/goz061","volume":"8","author":"N Huyghe","year":"2020","unstructured":"Huyghe, N. et al. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol. Rep. (Oxf.) 8, 11\u201324 (2020).","journal-title":"Gastroenterol. Rep. (Oxf.)"},{"key":"57965_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk, J. S. et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28\u201351 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"57965_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","volume":"161","author":"G Pasut","year":"2012","unstructured":"Pasut, G. et al. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control Release 161, 461\u2013472 (2012).","journal-title":"J. Control Release"},{"key":"57965_CR26","doi-asserted-by":"publisher","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","volume":"112","author":"RL Maute","year":"2015","unstructured":"Maute, R. L. et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc. Natl Acad. Sci. USA 112, E6506\u2013E6514 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57965_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco, L. M. et al. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219\u2013242 (2010).","journal-title":"Immunol. Rev."},{"key":"57965_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0014-5793(98)01574-9","volume":"441","author":"JM Chen","year":"1998","unstructured":"Chen, J. M. et al. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett. 441, 361\u2013365 (1998).","journal-title":"FEBS Lett."},{"key":"57965_CR29","doi-asserted-by":"publisher","first-page":"10940","DOI":"10.1073\/pnas.1300686110","volume":"110","author":"E Dall","year":"2013","unstructured":"Dall, E. et al. Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation. Proc. Natl Acad. Sci. USA 110, 10940\u201310945 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57965_CR30","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1096\/fj.10-172312","volume":"25","author":"G Miller","year":"2011","unstructured":"Miller, G. et al. Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J. 25, 1606\u20131617 (2011).","journal-title":"FASEB J."},{"key":"57965_CR31","first-page":"2957","volume":"63","author":"C Liu","year":"2003","unstructured":"Liu, C. et al. Overexpression of legumain in tumors is significant for invasion\/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63, 2957\u20132964 (2003).","journal-title":"Cancer Res."},{"key":"57965_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.biomaterials.2013.09.100","volume":"35","author":"YJ Chen","year":"2014","unstructured":"Chen, Y. J. et al. Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection. Biomaterials 35, 304\u2013315 (2014).","journal-title":"Biomaterials"},{"key":"57965_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0621-9","volume":"30","author":"N Li","year":"2013","unstructured":"Li, N. et al. Effects of legumain as a potential prognostic factor on gastric cancers. Med Oncol. 30, 621 (2013).","journal-title":"Med Oncol."},{"key":"57965_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","volume":"154-155","author":"S Shah","year":"2020","unstructured":"Shah, S. et al. Liposomes: advancements and innovation in the manufacturing process. Adv. Drug Deliv. Rev. 154-155, 102\u2013122 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"57965_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113851","volume":"176","author":"DE Large","year":"2021","unstructured":"Large, D. E. et al. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv. Drug Deliv. Rev. 176, 113851 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"57965_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fchem.2018.00237","volume":"6","author":"PM Carvalho","year":"2018","unstructured":"Carvalho, P. M. et al. Application of light scattering techniques to nanoparticle characterization and development. Front. Chem. 6, 237 (2018).","journal-title":"Front. Chem."},{"key":"57965_CR37","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1021\/jm701311r","volume":"51","author":"MG Gotz","year":"2008","unstructured":"Gotz, M. G. et al. Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens. J. Med. Chem. 51, 2816\u20132832 (2008).","journal-title":"J. Med. Chem."},{"key":"57965_CR38","doi-asserted-by":"publisher","first-page":"7192","DOI":"10.1021\/jm900849h","volume":"52","author":"A Ovat","year":"2009","unstructured":"Ovat, A. et al. Aza-peptidyl Michael acceptor and epoxide inhibitors-potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases). J. Med. Chem. 52, 7192\u20137210 (2009).","journal-title":"J. Med. Chem."},{"key":"57965_CR39","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1515\/BC.2002.133","volume":"383","author":"AJ Niestroj","year":"2002","unstructured":"Niestroj, A. J. et al. Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones. Biol. Chem. 383, 1205\u20131214 (2002).","journal-title":"Biol. Chem."},{"key":"57965_CR40","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1021\/jm049938j","volume":"47","author":"OD Ekici","year":"2004","unstructured":"Ekici, O. D. et al. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. J. Med. Chem. 47, 1889\u20131892 (2004).","journal-title":"J. Med. Chem."},{"key":"57965_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106200","volume":"130","author":"L Larue","year":"2023","unstructured":"Larue, L. et al. tLyp-1: A peptide suitable to target NRP-1 receptor. Bioorg. Chem. 130, 106200 (2023).","journal-title":"Bioorg. Chem."},{"key":"57965_CR42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361\u2013375 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"57965_CR43","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cac2.12412","volume":"43","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. Cancer Commun. (Lond.) 43, 435\u2013454 (2023).","journal-title":"Cancer Commun. (Lond.)"},{"key":"57965_CR44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.aau0447","volume":"364","author":"R Mandal","year":"2019","unstructured":"Mandal, R. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364, 485\u2013491 (2019).","journal-title":"Science"},{"key":"57965_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105323118","volume":"118","author":"WW Ho","year":"2021","unstructured":"Ho, W. W. et al. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc. Natl Acad. Sci. USA 118, e2105323118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57965_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5280","volume":"5","author":"Z Liu","year":"2014","unstructured":"Liu, Z. et al. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat. Commun. 5, 4280 (2014).","journal-title":"Nat. Commun."},{"key":"57965_CR47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/cr.2014.4","volume":"24","author":"L Zhao","year":"2014","unstructured":"Zhao, L. et al. Structural analysis of asparaginyl endopeptidase reveals the activation mechanism and a reversible intermediate maturation stage. Cell Res. 24, 344\u2013358 (2014).","journal-title":"Cell Res."},{"key":"57965_CR48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","volume":"157","author":"J Fang","year":"2020","unstructured":"Fang, J. et al. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug Deliv. Rev. 157, 142\u2013160 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"57965_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","volume":"91","author":"H Maeda","year":"2015","unstructured":"Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3\u20136 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"57965_CR50","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker, S. et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735\u2013745 (1998).","journal-title":"Cell"},{"key":"57965_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9","volume":"89","author":"A Latil","year":"2000","unstructured":"Latil, A. et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int. J. Cancer 89, 167\u2013171 (2000).","journal-title":"Int. J. Cancer"},{"key":"57965_CR52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos, A. Development of immuno-oncology drugs\u2014from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235\u2013247 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"57965_CR53","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney, K. M. et al. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561\u2013584 (2015).","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57965-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:56:36Z","timestamp":1742957796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57965-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["57965"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-57965-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"24 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2854"}}